# Shenqi Dihuang Decoction Attenuates ALOX5‐Mediated Ferroptosis in Diabetic Nephropathy via AMPK/mTOR and TGF‐β/Smads Pathways

**Authors:** Li Zhao, Danna Zheng, Wenjuan Gu, Yanna Liu, Jinlong Lyu

PMC · DOI: 10.1155/jdr/2872977 · Journal of Diabetes Research · 2026-03-03

## TL;DR

This study shows that Shenqi Dihuang Decoction reduces kidney damage in diabetic mice by targeting ALOX5 and related pathways.

## Contribution

The study identifies ALOX5-mediated ferroptosis as a novel mechanism in diabetic nephropathy and demonstrates how SDD modulates AMPK/mTOR and TGF-β/Smads pathways.

## Key findings

- SDD improves kidney function and reduces fibrosis and inflammation in diabetic nephropathy.
- SDD inhibits ALOX5 and ferroptosis markers while modulating AMPK/mTOR and TGF-β/Smads pathways.
- Upregulation of ALOX5 reverses the protective effects of SDD, confirming its role in the mechanism.

## Abstract

To explore the underlying mechanisms about that Shenqi Dihuang decoction (SDD) attenuated diabetic nephropathy (DN), mice were fed on high‐sugar and high‐fat diet and treated with streptozotocin (STZ) to induce DN model, as well as HK‐2 cells treated with D‐glucose to establish a DN cell model. High‐performance liquid chromatography (HPLC) analysis was carried out to excavate the chemical compositions existed in SDD. The network pharmacological analysis was performed to screen the key genes involved in SDD treating DN. Subsequently, the effects of SDD on ALOX5, ferroptosis‐ and AMPK/mTOR pathway‐associated indices were examined. Finally, whether SDD attenuated ALOX5‐mediated ferroptosis in DN via AMPK/mTOR and TGF‐β/Smads pathways were validated using gain‐of‐function experiment. SDD exerted a therapeutic effect on DN mice by improving kidney function, kidney fibrosis and reducing inflammation. HPLC analysis detected two chemical compositions in SDD, containing syringic acid and gallic acid ethyl ester. Network pharmacological analysis found that SDD might inhibit DN by targeting ALOX5. In addition, SDD treatment decreased ROS, MDA, iron, ALOX5, p‐mTOR/mTOR, TGF‐β1, p‐Smad2/3/Smad2/3 levels in DN, whereas elevated the levels of SLC7A11, GPX4 and p‐AMPK/AMPK. These changes were reversed upon upregulation of ALOX5 gene expression. In conclusion, SDD inhibits ALOX5‐mediated ferroptosis in DN via AMPK/mTOR and TGF‐β/Smads pathways.

## Linked entities

- **Genes:** ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240], SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], SMAD2 (SMAD family member 2) [NCBI Gene 4087], SMAD3 (SMAD family member 3) [NCBI Gene 4088]
- **Chemicals:** syringic acid (PubChem CID 10742), gallic acid ethyl ester (PubChem CID 13250), MDA (PubChem CID 1614), iron (PubChem CID 23925)
- **Diseases:** diabetic nephropathy (MONDO:0005016)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Dock2 (dedicator of cyto-kinesis 2) [NCBI Gene 94176] {aka CED-5, Hch, MBC}, Alox5 (arachidonate 5-lipoxygenase) [NCBI Gene 11689] {aka 5-LO, 5-LOX, 5LO, 5LX, F730011J02}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, Ctsb (cathepsin B) [NCBI Gene 13030] {aka APPM, CB}, Slc7a11 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 11) [NCBI Gene 26570] {aka 9930009M05Rik, sut, xCT}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240] {aka 5-LO, 5-LOX, 5LPG, LOG5}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Hdac6 (histone deacetylase 6) [NCBI Gene 15185] {aka Hd6, Hdac5, Sfc6, mHDA2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}
- **Diseases:** DN (MESH:D003928), metabolic disease (MESH:D008659), mesangial hyperplasia (MESH:D006965), proteinuria (MESH:D011507), T2DM (MESH:D003924), glomerular sclerosis (MESH:D007674), cardiovascular diseases (MESH:D002318), DM (MESH:D003920), end-stage renal disease (MESH:D007676), cancer (MESH:D009369), atrophy of the renal tubules (MESH:D007673), neurodegenerative disorders (MESH:D019636), inflammation (MESH:D007249), melanoma (MESH:D008545), fibrosis (MESH:D005355)
- **Chemicals:** D-glucose (MESH:D005947), creatinine (MESH:D003404), syringic acid (MESH:C001945), blood glucose (MESH:D001786), Irbesartan (MESH:D000077405), ROS (MESH:D017382), sirius (MESH:C433343), PVDF (MESH:C024865), germacrone (MESH:C048393), SDS (MESH:D012967), arachidonic acid (MESH:D016718), urea nitrogen (MESH:C530477), paraformaldehyde (MESH:C003043), lipid (MESH:D008055), Iron (MESH:D007501), Trizol (MESH:C411644), STZ (MESH:D013311), CCK-8 (MESH:D012844), water (MESH:D014867), telazol (MESH:C006131), CO2 (MESH:D002245), Kaempferol (MESH:C006552), acetonitrile (MESH:C032159), streptomycin (MESH:D013307), MDA (MESH:D008315), phosphoric acid (MESH:C030242), MDA (MESH:D015104), quercetin (MESH:D011794), HG (MESH:D008628), sodium citrate (MESH:D000077559), sugar (MESH:D000073893), penicillin (MESH:D010406), erastin (MESH:C477224), fenofibrate (MESH:D011345), AF4699 (-), fat (MESH:D005223), paraffin (MESH:D010232), kirenol (MESH:C560087), methanol (MESH:D000432), sodium chloride (MESH:D012965)
- **Species:** Panax ginseng (Asiatic ginseng, species) [taxon 4054], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957774/full.md

## Figures

32 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957774/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957774/full.md

---
Source: https://tomesphere.com/paper/PMC12957774